rs116052952 - LINC02991 - NDUFA10
Magnitude 2.2 · 1 study on file
Reported associations
-
Antidepressant Switching as a Proxy Phenotype for Drug Nonresponse: Investigating Clinical, Demographic, and Genetic Characteristics - Unknown journal (n.d.) · Unknown authors · PubMed 40510220
ABSTRACT: Background Selective serotonin reuptake inhibitors (SSRIs) are a first-line pharmacological therapy in major depressive disorder (MDD), but treatment response rates are low. Clinical trials lack the power to study the genetic contribution to SSRI response. Real-world evidence from electronic health records provides larger sample sizes, but novel response definitions are needed to accurately define SSRI nonresponders. Methods In the UK Biobank (UKB) (N = 38,813) and Generation Scotland (N = 1777) datasets, SSRI switching was defined using ≤90-day gap between prescriptions for an SSRI and another antidepressant in primary care. Nonswitchers were participants with ≥3 consecutive prescriptions for an SSRI. In the UKB, clinical, demographic, and polygenic score (PGS) associations
Auto-generated from study metadata. AI-synthesised commentary is added when this entry is regenerated through content-service's LLM mode.
Lifestyle context
Concrete actions anchored to the cited research. We do not prescribe, we describe.
Discuss with your doctor
-
SSRI pharmacogenetic factors and treatment plan Moderate
Genetic variant associated with increased SSRI switching in depression; discussing treatment optimization options with prescriber can improve outcomes
Before initiating SSRI or if experiencing inadequate response, discuss genetic findings and monitoring plan with psychiatrist
Screening
-
SSRI efficacy and tolerability during initial treatment Moderate
Genetic predisposition to SSRI switching suggests need for close monitoring to detect inadequate response or side effects early
Schedule follow-up assessments at 2-4 weeks after SSRI initiation and as clinically indicated